Castle Biosciences, Inc. - SIC # 8081 -

Ticker Exchange SIC # Website Latest Ticker
CSTL Nasdaq 8081 castlebiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences - Aug 20th, 2026 5:00 am
Castle Biosciences Approved for Dual Listing on Nasdaq Texas - Aug 17th, 2026 5:00 am
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction - Aug 12th, 2026 11:01 pm
Castle Biosciences, Inc. Q2 2026 Earnings Call Summary - Jul 31st, 2026 6:30 am
Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ... - Jul 30th, 2026 11:03 pm
Castle Biosciences Q2 Earnings Call Highlights - Jul 30th, 2026 4:04 pm
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates - Jul 30th, 2026 4:00 pm
Castle Biosciences Reports Second Quarter 2026 Results - Jul 30th, 2026 2:05 pm
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference - Jul 22nd, 2026 5:00 am
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - Jul 14th, 2026 2:30 pm
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 - Jul 9th, 2026 5:00 am
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Jun 26th, 2026 4:07 am
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - Jun 25th, 2026 2:30 pm
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal - Jun 23rd, 2026 5:00 am
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 19th, 2026 5:00 am
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - Jun 16th, 2026 5:00 am
How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary - Jun 9th, 2026 5:07 am
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets - May 24th, 2026 10:13 am